Outcome |
Relative effect (95% CI) |
Absolute effect (95% CI)1 |
Certainty of the Evidence (GRADE) |
Clinical improvement D28 |
RR: 1.51 (1.06 - 2.15) |
322 more per 1000 (from 38 more to 726 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Serious due to wide confidence interval consistent with the possibility for benefit and the possibility for no effect/trivial effect
|
1 trials
Cremer P, 2021
40 participants
|
|
Mavrilimumab 954 per 1,000 (669 - 1000) |
Placebo 632 per 1,000 |
|
Clinical improvement D60 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above) D28 |
RR: 0.23 (0.03 - 1.85) |
162 fewer per 1000 (from 204 fewer to 179 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
1 trials
Cremer P, 2021
40 participants
|
|
Mavrilimumab 48 per 1,000 (6 - 389) |
Placebo 211 per 1,000 |
|
WHO progression score (level 7 or above) D60 |
Outcome not yet measured or reported
|
|
All-cause mortality D28 |
RR: 0.3 (0.03 - 2.66) |
111 fewer per 1000 (from 153 fewer to 262 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
1 trials
Cremer P, 2021
40 participants
|
|
Mavrilimumab 47 per 1,000 (5 - 420) |
Placebo 158 per 1,000 |
|
All-cause mortality D60 |
RR: 0.23 (0.03 - 1.85) |
162 fewer per 1000 (from 204 fewer to 179 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
1 trials
Cremer P, 2021
40 participants
|
|
Mavrilimumab 48 per 1,000 (6 - 389) |
Placebo 211 per 1,000 |
|
Viral negative conversion D7 |
Outcome not yet measured or reported
|
|
Adverse events
|
Outcome not yet measured or reported
|
|
Serious adverse events
|
RR: 1.13 (0.35 - 3.6) |
27 more per 1000 (from 137 fewer to 547 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Serious despite a multicentre design this is a single study from a single country, therefore results in this population might not be generalizable to other settings. Imprecision: Very serious due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
1 trials
Cremer P, 2021
40 participants
|
|
Mavrilimumab 238 per 1,000 (74 - 758) |
Placebo 211 per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect